Immune Thrombocytopenia Market
Sep 22, 2025
Sanofi’s WAYRILZ Approval Ushers in New Era for Immune Thrombocytopenia Treatment
Immune thrombocytopenia is a rare autoimmune disorder, affecting both children and adults. The global incidence of ITP is estimated at around 2–5 cases per 100,000 people annually, with prevalence higher in adults and a slight female predominance. In 2024, the total cases of immune thrombocytopenia were approxim...
Read More...
Sep 02, 2025
FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s; Travere Therapeutics Gains FDA Nod for FILSPARI REMS Update in IgA Nephropathy; Vanda Pharmaceuticals’ VGT-1849B Granted FDA Orphan Drug Status for Polycythemia Vera; Teva Launches First FDA-Approved Generic SAXENDA for Weight Loss; Sanofi’s WAYRILZ Gets FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia
FDA Approves Eisai & Biogen’s LEQEMBI IQLIK for Maintenance Treatment of Early Alzheimer’s Eisai Co., Ltd. and Biogen Inc. announced that the FDA has approved the Biologics License Application (BLA) for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly 360 mg subcutaneous autoinjector designed for maintenance do...
Read More...
May 25, 2020
R&D and Upcoming therapies Paving the Way for a Potential and Better Cure for Immune Thrombocytopenia
The Immune Thrombocytopenia market size in the 7MM was estimated to be approximately USD 2,527.72 million in 2017. The US accounts for the largest ITP Market size. A disorder that results in an isolated low platelet count, Immune thrombocytopenia (ITP), is an autoimmune disorder that results in convincing body...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
